The Effect of Previous Coronary-Artery Bypass Surgery on the Prognosis of Patients with Diabetes Who Have Acute Myocardial Infarction

• Published in: The New England journal of medicine Vol. 342; no. 14; pp. 989 - 997
• Main Authors: Detre, Katherine M, Lombardero, Manuel S, Brooks, Maria Mori, Hardison, Regina M, Holubkov, Richard, Sopko, George, Frye, Robert L, Chaitman, Bernard R
• Format: Journal Article
• Language: English
• Published: Boston, MA Massachusetts Medical Society 06-04-2000
• Subjects: Angioplasty; Biological and medical sciences; Cardiology. Vascular system; Cardiovascular disease; Coronary heart disease; Heart; Heart attacks; Medical sciences; Mortality; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Surgery of the heart; Endocrinopathy; Human; Prognosis; Infarct; Angioplasty; Diabetes mellitus; Treatment efficiency; Surgical revascularization; Coronary artery; Cardiovascular disease; Coronary heart disease; Myocardial disease; Treatment; Bypass; Surgery; Myocardium; Comparative study
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJM200004063421401

In 1996, the Bypass Angioplasty Revascularization Investigation (BARI), a randomized trial, found that an initial strategy of coronary-artery bypass grafting (CABG), as compared with percutaneous transluminal coronary angioplasty (PTCA), significantly improved five-year survival among patients with medically treated diabetes.
1
,
2
This benefit was not observed in the periprocedural period; rather, it was a sustained, long-term effect, with the risk of death consistently reduced by about 50 percent throughout the five years of follow-up. No difference in survival was observed in this study among the patients who did not have diabetes. After eight years of follow-up, the Emory Angioplasty versus Surgery . . .